Evaluation of the Prognostic Value and TRIP13 gene Expression in Gastric Cancer

Highlights

References

• 1.
  Sitarz R, Skierucha M, Mielko J, Offerhaus GJ, Maciejewski R, Polkowski WP. Gastric cancer: epidemiology, prevention, classification, and treatment. Cancer Manag Res 2018; 10: 239.
• 2.
  Lauren P. The two histological main types of gastric carcinoma: diffuse and socalled intestinaltype carcinoma. Acta Pathol Microbiol Scand 1965; 64: 31-49.
• 3.
  Kalbasi M, Siadati S, Kamali Ahangar S, Nikbakhsh N. Clinicopathologic Characteristics of Multifocal Gastric Adenocarcinoma. J Babol Univ Med Sci 2019; 21: 147-152. (Persian).
• 4.
  Thrift AP, Nguyen TH. Gastric cancer epidemiology. Gastrointest Endosc Clin N Am 2021; 31: 425-439.
• 5.
  Almasi Z, Rafiemanesh H, Salehiniya H. Epidemiology characteristics and trends of incidence and morphology of stomach cancer in Iran. Asian Pac J Cancer Prev 2015; 16: 2757-2761.
• 6.
  Samadani AA, Mansour-Ghanaie F, Joukar F, Safizadeh M, Nourollahi SE, Rashidy-Pour A. Performance of methylation and expression fluctuations of sonic hedgehog genes in gastric adenocarcinoma. Koomesh 2019; 21: 215-224. (Persian).
• 7.
  Henson DE, Dittus C, Younes M, Nguyen H, Albores-Saavedra J. Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973-2000: increase in the signet ring cell type. Arch Pathol Lab Med 2004; 128: 765-770.
• 8.
  Taja-Chayeb L, Vidal-Milln S, Trejo-Becerril C, Prez-Crdenas E, Chvez-Blanco A, Domnguez-Gmez G, et al. Hereditary diffuse gastric cancer (HDGC). An overview. Clin Res Hepatol Gastroenterol 2022; 46: 101820.
• 9.
  Behroozi J, Shahbazi S, Bakhtiarizadeh MR, Mahmoodzadeh H. ADAR expression and copy number variation in patients with advanced gastric cancer. BMC Gastroenterol 2020; 20: 1-9.
• 10.
  Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer. CA Cancer J Clin 2021; 71: 264-279.
• 11.
  Nadauld LD, Garcia S, Natsoulis G, Bell JM, Miotke L, Hopmans ES, et al. Metastatic tumor evolution and organoid modeling implicate TGFBR2as a cancer driver in diffuse gastric cancer. Genome Biol 2014; 15: 428.
• 12.
  Wang K, Yuen ST, Xu J, Lee SP, Yan HH, Shi ST, et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet 2014; 46: 573-582.
• 13.
  Liang L, Fang JY, Xu J. Gastric cancer and gene copy number variation: emerging cancer drivers for targeted therapy. Oncogene 2016; 35: 1475-1482.
• 14.
  Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013; 499: 214.
• 15.
  Niapour N, Shokri Gara Geshlagi S, Amani M, Sharifi Pasandi M, Salehi H, Niapour A. Effects of all trans retinoic acid on apoptosis induction and notch1, hes1 genes expression in gastric cancer cell line MKN-45. Koomesh 2016; 17: 1024-1032. (Persian).
• 16.
  Chen X, Leung SY, Yuen ST, Chu KM, Ji J, Li R, et al. Variation in gene expression patterns in human gastric cancers. Mol Biol Cell 2003; 14: 3208-3215.
• 17.
  Ramezankhani R, Solhi R, Es HA, Vosough M, Hassan M. Novel molecular targets in gastric adenocarcinoma. Pharmacol Ther 2021; 220: 107714.
• 18.
  Xie W, Wang S, Wang J, de la Cruz MJ, Xu G, Scaltriti M, et al. Molecular mechanisms of assembly and TRIP13-mediated remodeling of the human Shieldin complex. Proc Natl Acad Sci U S A 2021; 118.
• 19.
  Liu X, Shen X, Zhang J. TRIP13 exerts a cancerpromoting role in cervical cancer by enhancing Wnt/catenin signaling via ACTN4. Environ Toxicol 2021; 36: 1829-1840.
• 20.
  Vader G. Pch2 TRIP13: controlling cell division through regulation of HORMA domains. Chromosoma 2015; 124: 333-339.
• 21.
  Banerjee R, Russo N, Liu M, Basrur V, Bellile E, Palanisamy N, et al. TRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancer. Nat Commun 2014; 5: 1-18.
• 22.
  Clough E, Barrett T. The gene expression omnibus database. Methods Mol Biol 2016; 1418: 93-110.
• 23.
  Kim D, Langmead B, Salzberg SL. HISAT: a fast spliced aligner with low memory requirements. Nat Methods 2015; 12: 357.
• 24.
  Ebbert MT, Wadsworth ME, Staley LA, Hoyt KL, Pickett B, Miller J, et al. Evaluating the necessity of PCR duplicate removal from next-generation sequencing data and a comparison of approaches. BMC Bioinformatics 2016; 17: 239.
• 25.
  Tomczak K, Czerwiska P, Wiznerowicz M. The cancer genome atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn) 2015; 19: A68-77.
• 26.
  Szsz AM, Lnczky A, Nagy , Frster S, Hark K, Green JE, et al. Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients. Oncotarget 2016; 7: 49322.
• 27.
  Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012; 483: 603-607.
• 28.
  Sheng N, Yan L, Wu K, You W, Gong J, Hu L, et al. TRIP13 promotes tumor growth and is associated with poor prognosis in colorectal cancer. Cell Death Dis 2018; 9: 1-14.
• 29.
  Aziz NA, Mokhtar NM, Harun R, Mollah MM, Rose IM, Sagap I, et al. A 19-Gene expression signature as a predictor of survival in colorectal cancer. BMC Med Genomics 2016; 9: 58.
• 30.
  Agarwal S, Afaq F, Bajpai P, Kim HG, Elkholy A, Behring M, et al. DCZ0415, a smallmolecule inhibitor targeting TRIP13, inhibits EMT and metastasis via inactivation of the FGFR4/STAT3 axis and the Wnt/catenin pathway in colorectal cancer. Mol Oncol 2022; 16: 1728-1745.
• 31.
  Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, et al. Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci U S A 2004; 101: 9309-9314.
• 32.
  Martin KJ, Patrick DR, Bissell MJ, Fournier MV. Prognostic breast cancer signature identified from 3D culture model accurately predicts clinical outcome across independent datasets. PloS One 2008; 3: e2994.
• 33.
  Nieto-Jimnez C, Alcaraz-Sanabria A, Pez R, Prez-Pea J, Corrales-Snchez V, Pandiella A, et al. DNA-damage related genes and clinical outcome in hormone receptor positive breast cancer. Oncotarget 2017; 8: 62834.
• 34.
  Tao Y, Yang G, Yang H, Song D, Hu L, Xie B, et al. TRIP13 impairs mitotic checkpoint surveillance and is associated with poor prognosis in multiple myeloma. Oncotarget 2017; 8: 26718.
• 35.
  Van Kester MS, Borg MK, Zoutman WH, Out-Luiting JJ, Jansen PM, Dreef EJ, et al. A meta-analysis of gene expression data identifies a molecular signature characteristic for tumor-stage mycosis fungoides. J Invest Dermatol 2012; 132: 2050-2059.
• 36.
  Zhou K, Zhang W, Zhang Q, Gui R, Zhao H, Chai X, et al. Loss of thyroid hormone receptor interactor 13 inhibits cell proliferation and survival in human chronic lymphocytic leukemia. Oncotarget 2017; 8: 25469.
• 37.
  Bakhoum SF, Compton DA. Chromosomal instability and cancer: a complex relationship with therapeutic potential. J Clin Invest 2012; 122: 1138-1143.
• 38.
  Ma HT, Poon RY. TRIP13 functions in the establishment of the spindle assembly checkpoint by replenishing O-MAD2. Cell Reports 2018; 22: 1439-1450.
• 39.
  Wang K, Sturt-Gillespie B, Hittle JC, Macdonald D, Chan GK, Yen TJ, et al. Thyroid hormone receptor interacting protein 13 (TRIP13) AAA-ATPase is a novel mitotic checkpoint-silencing protein. J Biol Chem 2014; 289: 23928-23937.
• 40.
  Loo LW, Tiirikainen M, Cheng I, LumJones A, Seifried A, Church JM, et al. Integrated analysis of genomewide copy number alterations and gene expression in microsatellite stable, CpG island methylator phenotypenegative colon cancer. Genes Chromosomes Cancer 2013; 52: 450-466.
• 41.
  Yao J, Zhang X, Li J, Zhao D, Gao B, Zhou H, et al. Silencing TRIP13 inhibits cell growth and metastasis of hepatocellular carcinoma by activating of TGF-1/smad3. Cancer Cell Intern 2018; 18: 208.
• 42.
  Dazhi W, Mengxi Z, Fufeng C, Meixing Y. Elevated expression of thyroid hormone receptor-interacting protein 13 drives tumorigenesis and affects clinical outcome. Biomark Med 2017; 11: 19-31.
• 43.
  Maurizio E, Winiewski JR, Ciani Y, Amato A, Arnoldo L, Penzo C, et al. Translating proteomic into functional data: an high mobility group A1 (HMGA1) proteomic signature has prognostic value in breast cancer. Mol Cell Proteomics 2016; 15: 109-123.